{"entity":{"id":"nct05312710","kind":"trial","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","aka":[],"tldr":"A phase 2 trial of APG-157 in head and neck squamous cell carcinoma, run by Aveta Biomics, Inc., active and no longer recruiting.","summary":"Safety and Efficacy of APG-157 in Head and Neck Cancer is a phase 2 interventional study registered as NCT05312710 by Aveta Biomics, Inc., with 24 participants enrolled, started 2022-04-22 and due to reach its primary completion in 2026-12. Interventions recorded: APG-157.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05312710","url":"https://clinicaltrials.gov/study/NCT05312710"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aveta-biomics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05312710","phase":"2","setting":"Phase 2 Study to Evaluate the Safety and Efficacy of APG-157 as Neoadjuvant/Induction Therapy for Patients With Head and Neck Squamous Cell Cancer (HNSCC) of the Oral Cavity and/or Oropharynx","sponsor":"Aveta Biomics, Inc.","enrolled":24,"outcomes":[]},"route":"/trials/nct05312710/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/"}]}}